Company intelligence / Profile preview

Generate

Somerville/Cambridge/Andover/Boynton Yards*, Massachusetts, United Stateswix.com ↗

Ownership: Private
Employees: ~100
Development stage: Other

Overview

Generate Biomedicines has demonstrated rapid design and development of novel protein therapeutics using its AI-driven platform. Its lead program GB‑0669 entered first-in-human trials targeting a conserved region of the SARS-CoV‑2 spike protein. The company’s pipeline includes 17 programs across infectious disease, immunology, and oncology. No late-stage clinical results have been published yet.

Therapeutic areas: OncologyImmunologyInfectious Diseases
Modalities: AntibodyPeptidesEnzyme replacement therapyCytokineGene therapyModular proteins
Industry: Biotech

Partnerships

Novartis ($1B+ collaboration on generative AI-designed proteins)AmgenNVIDIA VC arm investmentacademic collaborations not specifically named but referenced as part of R&D model.

Beyond the preview

Go deeper on Generate.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Generate.

Explore the full profile